Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. has demonstrated potential for improved performance despite facing mixed results due to market dynamics and upcoming structural changes in reimbursement. The company is poised for growth, with a projected increase in operating profit as it capitalizes on an expansive portfolio of regenerative medicine products within an underpenetrated market. Additionally, favorable adjustments in reimbursement rates and a strategy focused on capturing market share in a consolidating space further bolster the outlook for the company's stock.

Bears say

Organogenesis Holdings Inc. faces a challenging outlook due to anticipated stagnation in financial performance, with no improvement expected in fiscal year 2026 from increased research and development costs, although a potential reduction in selling, general, and administrative expenses is noted. The company is at risk of insufficient growth in its PuraPly product line, coupled with adverse implications from Medicare Part B pricing on amniotic products and heightened competition that could limit market share gains. Additionally, the firm may encounter hurdles due to slower adoption rates for new products, regulatory challenges, and potentially negative clinical trial outcomes, all of which contribute to a negative sentiment about its future performance.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.